Asterixis Differential Diagnosis: A Comprehensive Guide for Clinicians

Asterixis, commonly referred to as flapping tremor, is a crucial clinical sign that indicates a patient’s inability to sustain a posture due to brief lapses in muscle contraction. This involuntary movement, initially termed “liver flap” by Raymond Adams and Joseph Foley in 1949 in the context of hepatic encephalopathy, is a form of negative myoclonus that is essential to recognize in a broad range of medical conditions.

While asterixis is predominantly observed in the muscles of the upper extremities, it can manifest in any muscle group throughout the body. It typically presents bilaterally and asynchronously, though unilateral and focal occurrences are also possible. Often, patients are unaware of asterixis, making its elicitation during a physical examination critical. The standard method to detect asterixis involves instructing the patient to extend their arms forward, dorsiflex the wrists, and fully extend their fingers while keeping their eyes closed. The presence of asterixis is indicated by a sudden, brief flapping or flexion movement at the wrist. Enhancing the sensitivity of this test can be achieved by gently applying pressure to the patient’s hands, encouraging further dorsiflexion. Asterixis in the lower extremities can be assessed by having the patient lie supine, flex the hip to lift the leg, extend the knee, and dorsiflex the ankle. A positive sign in the lower limb is a flap at the ankle joint or a quick, momentary lowering of the leg. If full knee extension is not possible, the leg can be examined in a flexed position.

The detection of asterixis is a significant clinical finding, often pointing towards an underlying medical or neurological condition. Toxic-metabolic encephalopathy is the most frequent cause. Although delirium may or may not be present, asterixis often accompanies other indicators of toxic-metabolic encephalopathy, such as multifocal myoclonus and tremor. Furthermore, structural brain lesions, including strokes, epidural and subdural hematomas, and brain tumors, can also induce asterixis. Importantly, asterixis is generally reversible, resolving once the underlying cause is effectively treated.

Understanding the Pathophysiology of Asterixis

The precise mechanism behind asterixis remains an area of ongoing research. Current theories suggest that disruptions within the ascending reticular activating system (ARAS), which plays a vital role in arousal and consciousness, are implicated. This system is known to be affected in encephalopathies and lesions involving the thalamus and midbrain. The clinical appearance of asterixis is a result of a transient failure to maintain sustained muscle contraction. This leads to brief silences in electromyographic (EMG) activity of the affected muscles, followed by compensatory bursts of activity as the body attempts to regain posture. These lapses in muscle tone are irregular and brief, resulting in the characteristic flapping movement.

Differential Diagnosis of Asterixis

When asterixis is observed, a systematic approach to differential diagnosis is essential. The broad categories to consider include metabolic encephalopathies, toxic encephalopathies, and structural brain lesions.

1. Metabolic Encephalopathies:

Metabolic disturbances are the most common culprits behind asterixis. These conditions disrupt neuronal function due to systemic biochemical imbalances. Key metabolic encephalopathies associated with asterixis include:

• Hepatic Encephalopathy: Liver dysfunction leading to the accumulation of toxins like ammonia. Asterixis, historically known as the “liver flap,” is a hallmark sign. Other symptoms include altered mental status, confusion, and personality changes.

• Uremic Encephalopathy: Kidney failure results in the buildup of uremic toxins. Asterixis in uremia often co-occurs with tremors, myoclonus, and cognitive impairment.

• Respiratory Encephalopathy: Conditions causing hypercapnia (elevated CO2) or hypoxia (low oxygen) can lead to asterixis. Chronic obstructive pulmonary disease (COPD) is a common underlying condition.

• Electrolyte Imbalances: Severe derangements in electrolytes, such as hyponatremia, hypernatremia, hypokalemia, hypercalcemia, and hypomagnesemia can induce encephalopathy and asterixis.

• Hyperammonemia (Non-hepatic): Conditions beyond liver disease, such as urea cycle disorders, can cause elevated ammonia levels and encephalopathy with asterixis.

2. Toxic Encephalopathies:

Exposure to various toxins, particularly medications, can precipitate asterixis. Drug-induced asterixis should be considered, especially in patients with polypharmacy or recent medication changes. Common medications associated with asterixis include:

• Anticonvulsants: Valproate, phenytoin, carbamazepine, and gabapentin are known to cause asterixis. Valproate-induced hyperammonemia is a specific mechanism to consider.

• Antibiotics: Cefepime and other antibiotics, particularly beta-lactams, have been linked to encephalopathy and asterixis, especially in patients with renal impairment.

• Antipsychotics: Clozapine and other antipsychotic medications can induce asterixis.

• Benzodiazepines: While less common, benzodiazepines like lorazepam can also contribute to asterixis, particularly in overdose or withdrawal.

• Alcohol: Both alcohol intoxication and withdrawal can be associated with asterixis.

3. Structural Brain Lesions:

Focal brain lesions can also cause asterixis, although this is less frequent than metabolic or toxic etiologies. Asterixis due to structural lesions often presents unilaterally, aiding in differentiation. Key considerations include:

• Thalamic Lesions: The thalamus plays a critical role in motor control and arousal. Lesions in the thalamus are the most common structural cause of asterixis. The asterixis is typically contralateral to the lesion.

• Cerebellar Lesions: Cerebellar pathology can also result in asterixis, which, in contrast to thalamic lesions, is typically ipsilateral to the side of the lesion.

• Other Lesions: Strokes, tumors, hemorrhages, and demyelinating lesions in various brain regions, including the midbrain and parietal lobe, have been reported to cause asterixis. Bilateral asterixis can occur with bilateral or diffuse structural brain pathology.

4. Other Considerations:

While less common, other conditions should be considered in the differential diagnosis of asterixis:

• Wilson’s Disease: This genetic disorder of copper metabolism can present with neurological symptoms, including asterixis.

• Critical Illness Myopathy/Polyneuropathy: In severely ill patients, muscle weakness and neuromuscular junction dysfunction can mimic asterixis, although true asterixis involves involuntary lapses in posture, not simply weakness.

Clinical Significance and Diagnostic Approach

Asterixis is a valuable clinical sign that warrants careful attention, especially when evaluating patients for potential toxic-metabolic encephalopathy. It can be an early indicator of underlying systemic illness, even in the absence of other overt neurological signs. The presence of asterixis, particularly when combined with multifocal myoclonus and altered mental status, strongly suggests metabolic encephalopathy.

When asterixis is detected, a thorough diagnostic approach is crucial:

1. Detailed History: Obtain a comprehensive medical history, including pre-existing conditions (liver, kidney, lung, heart disease), medication history (prescription, over-the-counter, supplements), alcohol and substance use, and recent symptom onset. Inquire about subtle symptoms the patient may have overlooked, such as changes in handwriting or unexplained falls.

2. Physical Examination: Conduct a complete neurological examination to assess for other signs of encephalopathy, such as altered mental status, cognitive deficits, focal neurological signs, and other movement disorders like tremor and myoclonus. Pay close attention to eliciting asterixis in both upper and lower extremities.

3. Laboratory Investigations: Initial blood work should include:

   • Complete metabolic panel (CMP): Electrolytes, liver function tests (LFTs), renal function tests (RFTs), glucose.
   • Serum ammonia level: Especially important if hepatic encephalopathy is suspected.
   • Arterial blood gas (ABG): To assess for hypercapnia or hypoxia.
   • Drug levels: If medication-induced asterixis is suspected (e.g., valproate level).
   • Urine toxicology screen: If substance abuse is a concern.

4. Neuroimaging: If structural brain lesions are suspected (e.g., unilateral asterixis, focal neurological deficits, sudden onset), brain imaging, preferably MRI or CT scan, is indicated.

5. Electroencephalography (EEG): EEG can be helpful to evaluate for encephalopathic changes and rule out non-convulsive seizures, although it is not specifically diagnostic for asterixis.

Conclusion

Asterixis is a critical clinical sign that serves as a valuable indicator of underlying neurological or systemic dysfunction. While most commonly associated with metabolic encephalopathies, particularly hepatic encephalopathy, a broad differential diagnosis encompassing toxic and structural causes must be considered. A systematic diagnostic approach, including thorough history, physical examination, targeted laboratory investigations, and neuroimaging when appropriate, is essential to identify the underlying etiology and guide appropriate management. Recognizing asterixis and understanding its differential diagnosis allows clinicians to promptly address potentially serious underlying conditions and improve patient outcomes.

References

1. ADAMS RD, FOLEY JM. The neurological disorder associated with liver disease. Res Publ Assoc Res Nerv Ment Dis. 1953;32:198-237. [PubMed: 13134644]
2. Rissardo JP, Muhammad S, Yatakarla V, Vora NM, Paras P, Caprara ALF. Flapping Tremor: Unraveling Asterixis-A Narrative Review. Medicina (Kaunas). 2024 Feb 21;60(3) [PMC free article: PMC10972428] [PubMed: 38541088]
3. Ellul MA, Cross TJ, Larner AJ. Asterixis. Pract Neurol. 2017 Jan;17(1):60-62. [PubMed: 27807107]
4. Butz M, Timmermann L, Gross J, Pollok B, Südmeyer M, Kircheis G, Häussinger D, Schnitzler A. Cortical activation associated with asterixis in manifest hepatic encephalopathy. Acta Neurol Scand. 2014 Oct;130(4):260-7. [PubMed: 24372275]
5. Babiy M, Stubblefield MD, Herklotz M, Hand M. Asterixis related to gabapentin as a cause of falls. Am J Phys Med Rehabil. 2005 Feb;84(2):136-40. [PubMed: 15668562]
6. Formentin C, Zarantonello L, Mangini C, Angeli P, Merkel C, Montagnese S. Clinical value of asterixis in 374 well-characterised patients with cirrhosis and varying degree of hepatic encephalopathy. Dig Liver Dis. 2020 Feb;52(2):235-236. [PubMed: 31582327]
7. Santamaría Cano J, Graus Ribas F, Martínez Matos J, Rubio Borrero F, Arbizu Urdiain T, Peres Serra J. [Asterixis in focal lesions of the nervous system]. Rev Clin Esp. 1983 Jan 15;168(1):37-9. [PubMed: 6844678]
8. Berisavac II, Jovanović DR, Padjen VV, Ercegovac MD, Stanarčević PD, Budimkić-Stefanović MS, Radović MM, Beslać-Bumbaširević LG. How to recognize and treat metabolic encephalopathy in Neurology intensive care unit. Neurol India. 2017 Jan-Feb;65(1):123-128. [PubMed: 28084256]
9. Larson AM. Diagnosis and management of acute liver failure. Curr Opin Gastroenterol. 2010 May;26(3):214-21. [PubMed: 20216412]
10. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, Arroliga AC, Mullen KD. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003 Feb 15;114(3):188-93. [PubMed: 12637132]
11. Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, Witherden E, Støy S, Manakkat Vijay GK, Pons N, Galleron N, Huang X, Gencer S, Coen M, Tranah TH, Wendon JA, Bruce KD, Le Chatelier E, Ehrlich SD, Edwards LA, Shoaie S, Shawcross DL. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 2022 Feb;76(2):332-342. [PubMed: 34571050]
12. Safarpour Y, Vaziri ND, Jabbari B. Movement Disorders in Chronic Kidney Disease – A Descriptive Review. J Stroke Cerebrovasc Dis. 2021 Sep;30(9):105408. [PubMed: 33139171]
13. Conn HO. Asterixis. Its occurrence in chronic pulmonary disease, with a commentary on its general mechanism. N Engl J Med. 1958 Sep 18;259(12):564-9. [PubMed: 13578106]
14. Seifter JL, Samuels MA. Uremic encephalopathy and other brain disorders associated with renal failure. Semin Neurol. 2011 Apr;31(2):139-43. [PubMed: 21590619]
15. Nayak R, Pandurangi A, Bhogale G, Patil N, Chate S. Asterixis (flapping tremors) as an outcome of complex psychotropic drug interaction. J Neuropsychiatry Clin Neurosci. 2012 Winter;24(1):E26-7. [PubMed: 22450635]
16. Friedman JH. Clinically Determined Asterixis Is Markedly Increased in Patients Taking Clozapine. 2023 Mar-Apr 01Clin Neuropharmacol. 46(2):87. [PubMed: 36790372]
17. Velasco F, Gomez JC, Zarranz JJ, Lambarri I, Ugalde J. [Asterixis in focal brain lesions]. Neurologia. 2004 May;19(4):225-9. [PubMed: 15131742]
18. Degos JD, Verroust J, Bouchareine A, Serdaru M, Barbizet J. Asterixis in focal brain lesions. Arch Neurol. 1979 Nov;36(11):705-7. [PubMed: 508129]